Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LY4052031

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Solid TumorRecruiting

Metastatic Solid TumorPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Metastatic Solid Tumor

NCT06465069

Clinical

Trials by Indication[1]

Metastatic Solid Tumor1 trial

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06465069·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4052031. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4052031 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4052031. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

Related News